Fig. 4.

Prediction and identification of the upstream lncRNAs interacting with hsa-miR-27b-3p in HCC. (A) Candidate lncRNAs interacting with hsa-miR-27b-3p established by Cytoscape software. (B–C) The expression of TUG1, STAG3L5P-PVRIG2P-PILRB, PVT1, LINC01089, HCP5, GUSBP11, and AL450992.2 in TCGA HCC compared to “TCGA normal” data. Correlation analysis between HCP5 and hsa-miR-27b-3p (D) or HCP5 and LGALS3 (E) in HCC analyzed by ENCORI database. (F) qRT-PCR analysis of HCP5 expression in tumor and adjacent normal tissues from 5 HCC patients. (G) The differential expression of HCP5 in HCC with various tumor grades assessed by UALCAN. (H) Schematic representation of the 3′UTR of HCP5 with the predicted target site for hsa-miR-27b-3p. *p value＜ 0.05 ; **p value < 0.01; ***p value < 0.001